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Major depressive disorder (MDD) remains a huge personal and societal encumbrance. 
Particularly burdensome is a virulent subtype of MDD, treatment resistant major depres-
sion (TMRD), which afflicts 15–30% of MDD patients. There has been recent interest in 
N-methyl-d-aspartate receptors (NMDARs) as targets for treatment of MDD and perhaps 
TMRD. To date, most pre-clinical and clinical studies have focused on ketamine, although 
psychotomimetic and other side effects may limit ketamine’s utility. These considerations 
prompted a recent promising pilot clinical trial of nitrous oxide, an NMDAR antagonist 
that acts through a mechanism distinct from that of ketamine, in patients with severe 
TRMD. In this paper, we review the clinical picture of TRMD as a subtype of MDD, the 
evolution of ketamine as a fast-acting antidepressant, and clinical and basic science 
studies supporting the possible use of nitrous oxide as a rapid antidepressant.
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iNTRODUCTiON
Major depressive disorder (MDD) is a common and costly psychiatric illness resulting in substantial 
suffering and death (1–4). While current treatments for MDD are effective, they are typically slow 
to work requiring weeks of administration before significant benefits are observed, and are associ-
ated with side effects that limit efficacy and patient tolerance (5). Compounding these problems, 
Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; BDI, Beck depression inventory; 
BDNF, brain-derived neurotrophic factor; BP, bipolar disorder; CNS, central nervous system; CRPS, chronic regional pain 
syndrome; CBT, cognitive-behavioral therapy; DSM-V, Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition; 
EMA, ecological momentary assessments; ECT, electroconvulsive therapy; EEG, electroencephalogram; fMRI, functional 
magnetic resonance imaging; GABA, γ-aminobutyric acid; EC50, half-maximal effective concentration; HDRS, Hamilton 
Depression Rating Scale; HVA, high voltage-activated calcium currents; IPT, interpersonal therapy; LTD, long-term depression; 
LTP, long-term potentiation; LVA, low voltage activated calcium currents; MADRS, Montgomery–Asberg Depression Rating 
Scale; MAOIs, monoamine oxidase inhibitors; MCO, metal catalyzed oxidation; MDD, major depressive disorder; mTOR, 
mammalian target of rapamycin; NO, nitric oxide; NMDARs, N-methyl-d-aspartate receptors; PCP, phencyclidine; PTSD, 
post-traumatic stress disorder; ROS, reactive oxygen species; rTMS, repetitive transcranial magnetic stimulation; SSRIs, selec-
tive serotonin reuptake inhibitors; SNRIs, serotonin and norepinephrine uptake inhibitors; TCAs, tricyclic antidepressants; 
TRMD, treatment-resistant major depression; VAS, visual analog scales; VNS, vagus nerve stimulation.
FiGURe 1 | The scheme lists symptoms of depression according to 
changes in brain networks underlying emotion, motivation and 
cognition. Sleep disturbances may reflect homeostatic corrective efforts.
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about 15–30% of patients with MDD fail to respond to available 
treatments (6). These latter features have prompted the need to 
identify faster and more efficacious antidepressant strategies.
Dating to studies initiated in the late 1990s (7), there is increas-
ing evidence that the dissociative anesthetic, ketamine, has rapid 
antidepressant efficacy in subjects with MDD, including those 
with treatment-resistant major depression (TRMD). Ketamine 
differs from currently available antidepressant medications 
in being a non-competitive, use-dependent inhibitor of the 
N-methyl-d-aspartate class of glutamate receptors (NMDARs), 
and thus brings a potentially novel mechanism into play in 
developing new MDD treatments (8). Ketamine, however, is also 
a psychotomimetic, and in fact has been studied as such (9). This 
has prompted efforts to identify other NMDAR antagonists that 
have fewer side effects and more prolonged antidepressant effects 
compared to ketamine. Work from our labs years ago identified 
nitrous oxide as an NMDAR antagonist with mechanisms distinct 
from those of ketamine (10). Nagele et al. (11) recently conducted 
a pilot, proof-of-concept study using nitrous oxide (“laughing 
gas”) inhalation, as a potential treatment for TRMD. Although 
tempting to speculate that clinical benefit arises from NMDAR 
antagonism, nitrous oxide has other potential cellular targets that 
should be considered. In this paper, we will review the concepts 
of MDD and TRMD, the use of ketamine for TRMD, and work 
describing the actions and potential mechanisms of nitrous oxide 
as a rapidly acting antidepressant. The review is aimed at neuro-
scientists and those working in mental health fields.
MAJOR DePReSSive DiSORDeR
Major depressive disorder is among the leading causes of disabil-
ity, with disability defined as an inability to work productively or 
to live independently (3). Furthermore, MDD is a leading cause 
of suicide, and the presence of depression adds to the burden and 
adverse outcomes of primary medical illnesses, including heart 
disease, diabetes and cancer, among others (4). Current treatments 
for MDD include multiple classes of medications, a variety of 
neuromodulation treatments including electroconvulsive therapy 
(ECT), repetitive transcranial magnetic stimulation (rTMS), and 
vagus nerve stimulation (VNS), as well as evidence-based forms 
of psychotherapy such as cognitive-behavioral therapy (CBT) and 
interpersonal therapy (IPT).
As currently defined, MDD is a syndrome, meaning a collection 
of symptoms of undefined etiology that occur together over time. 
In the American Psychiatric Associations’ current Diagnostic and 
Statistical Manual of Mental Disorders-Fifth Edition (DSM-V) 
(12), a major depressive episode is characterized by a subset of 
nine clinical symptoms. These symptoms include: (1) low (sad) 
mood, (2) loss of interest in usual, particularly pleasurable activi-
ties, (3) change in appetite and body weight, (4) sleep disturbance, 
(5) dampened energy levels (fatigue), (6) increased (agitation) or 
decreased (retardation) motor activity, (7) feelings of excessive guilt 
and/or worthlessness, (8) diminished ability to focus attention and 
concentrate, and (9) recurrent thoughts of death and suicide.
The various symptoms of MDD can be difficult to conceptualize, 
but include symptoms that are associated with reactions to severe 
and persistent stressors. An alternative way to characterize the 
various symptoms is to view them in terms of brain networks that 
are dysfunctional in major psychiatric illnesses, the networks that 
underlie emotional processing, motivation, and cognition (13). 
In this context, the low mood of depression likely reflects changes 
in the circuitry underlying emotional regulation (the ability to 
attach meaning to things and people). Certain other symptoms 
reflect abnormalities in cognition including the ability to focus 
attention and to hold items in working memory for processing 
(reflected in poor concentration and memory difficulties). MDD 
is also associated with significant changes in the brain’s motiva-
tion/reward system, the circuitry that allows humans to set goals 
and work toward those goals. One can interpret the problems 
with loss of interest in pleasurable activities, changes in appetite 
and energy levels, altered movements, and even suicidal ideation 
in this context (Figure 1).
It is important to emphasize that MDD is unlikely a single 
illness (13). Rather multiple illnesses of differing etiologies can 
produce this collection of symptoms. Furthermore, even within 
a given etiology, some individuals will have almost completely 
different symptoms, given that only five of nine symptoms are 
required for the MDD diagnosis. Furthermore, multiple subtypes 
of depression can be described depending on co-morbid condi-
tions. Some patients with MDD have a heavy familial diathesis for 
MDD but do not meet diagnostic criteria for any other psychi-
atric disorder. In an older nomenclature, these individuals were 
described as having “primary” depression (sometimes called 
familial pure depression), meaning that MDD was the first, and in 
many cases, the only psychiatric disorder present (14). Similarly, 
individuals with bipolar disorder (BP) who experience episodes 
of both mania and MDD exhibit depressive symptoms that are 
often identical to persons who only have depression. Yet, the 
courses of their illness and their responses to treatments, while 
overlapping, have important differences. Further complicating 
the MDD diagnosis, individuals with psychosis (delusions and/
or hallucinations) in the context of MDD require treatments that 
differ from MDD uncomplicated by psychotic symptoms. Similar 
considerations can be given for MDD arising in the context 
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(and  subsequent to the onset) of other psychiatric disorders, 
including substance use disorders, personality disorders, anxiety 
disorders, obsessive–compulsive disorder, and post-traumatic 
stress disorder (PTSD). Similarly, MDD occurring in the pres-
ence of major medical illnesses can have a more complicated 
course in which the presence of MDD and the medical illnesses 
bi-directionally worsens outcomes (4). The complexities noted 
above also raise the likelihood that there can be vastly different 
responses to treatment across the spectrum of MDD, and large 
scale clinical effectiveness trials highlight this complexity (15).
TReATMeNT-ReSiSTANT MAJOR 
DePReSSiON
Given the heterogeneity of MDD, it is not surprising that the 
course of MDD can be highly variable, ranging from single 
episodes in some people to recurring and frequent episodes in 
others, and chronic unremitting symptoms in yet others. For 
most individuals, repeated episodes of illness are the norm with 
periods of illness typically ranging from several months to a 
year or longer. About 80% of persons with MDD have at least 
one recurrence during a lifetime, usually within 5 years of their 
initial episode (16), and individuals with an increased number of 
lifetime episodes require longer durations of treatment, in some 
cases, for life (17, 18). While current antidepressant treatments 
are effective, between 15 and 30% of individuals with pure MDD 
fail multiple treatments (1, 19–21).
Despite being relatively common in psychiatric practice, 
TRMD is not well defined across studies. In classifying individu-
als with MDD as being treatment resistant, it is important that 
refractoriness reflects treatment failure and not intolerance of 
side effects, treatment non-compliance, or inadequate dose/dura-
tion of treatment. Compounding this challenge is a problem with 
defining the degree of response to treatment. In clinical trials, 
treatment “response” is often defined as a 50% improvement in 
symptoms, whereas “remission” refers to having few or no residual 
symptoms following treatment using standardized instruments 
to rate symptoms including the Hamilton Depression Rating 
Scale (HDRS), the Montgomery–Asberg Depression Rating Scale 
(MADRS), and the Beck Depression Inventory (BDI), among 
others. Repeated studies demonstrate that remission is the goal 
of treatment; achieving remission gives the best chance to avoid 
MDD recurrence. Furthermore, “response” to treatment (50% 
improvement) can still reflect a state of significant dysfunction. 
MDD patients with multiple residual symptoms show increasing 
refractoriness to subsequent antidepressants trials (15).
Given the prevalence of MDD and TRMD, it is clear that 
TRMD is common, perhaps affecting as many as 3.5 million 
persons in the United States alone (1, 21). This ranks TRMD 
as more common than many disabling neurological conditions 
including epilepsy and multiple sclerosis (2). The early onset of 
TRMD, high medical utilization and disability also make TRMD 
very costly in terms of suffering, health care expenditures, and 
years of lost productivity.
There have been several attempts to characterize degrees of 
TRMD using clinical and treatment response criteria. In general, 
these efforts describe TRMD on an increasing scale of severity 
based on the number of “adequate” trials of antidepressant treat-
ment that have been failed, with “adequate” being defined by 
dose and duration of the trial. In a system devised by Thase and 
Rush (22), TRMD is rated on a 5-point scale with the most severe 
degree of refractoriness involving failure of multiple medications 
and a course of bilateral ECT. Fava (23) described a method 
for staging TRMD based on rating the adequacy of dosing and 
duration of treatment, use of augmentation strategies (e.g., 
lithium, anticonvulsants, stimulants, and buspirone), and ECT. 
The more recent Maudsley Staging Method for TRMD provides 
a multidimensional system based on clinical and treatment fac-
tors (24). The latter method involves documenting the number 
of treatment failures including ECT and augmentation strategies 
while taking into account symptom severity and illness duration.
In an effort to deal with the common problem of TRMD 
and its complexity, Conway and colleagues (25) established the 
Washington University TRMD Clinic. The goal of this clinic is to 
provide a systematic and comprehensive evaluation and consulta-
tion program for persons with well defined TRMD, focusing pri-
marily on patients with pure unipolar MDD. Individuals accepted 
into this clinic report histories of multiple, well-documented 
antidepressant treatment failures, but the program excludes 
patients with BPs, personality disorders, schizophrenia and/or 
schizoaffective disorder, active psychosis, or active substance use 
disorder (except nicotine use). Individuals in the TRMD clinic 
must also consent for release of all medical records so that diag-
noses and treatments can be adequately characterized by chart 
review plus clinical diagnostic interview.
Observations on the first 79 patients evaluated in the TRMD 
Clinic have been reported elsewhere (25) but are instructive and 
relevant to the pilot clinical study of nitrous oxide described 
below. Patients seen in the TRMD Clinic range in age from 19 
to 85 years and have an early onset of MDD, averaging 24.3 years 
of age at onset. This is consistent with previous studies also sug-
gesting that TRMD has a considerably earlier mean age of onset 
than non-TRMD depression (17, 20, 26, 27). The TRMD clinic 
patients were also found to have a high rate of mood disorder 
in first degree relatives: (62% having a first degree relative with 
MDD vs. 5.1–17.5% in the general MDD population (28), and 
14% having a first degree relative with BP).
Younger age of MDD onset was associated with family history 
(first or second degree relative) of mood disorder (r = −0.26, 
p  =  0.024; Figure  2) (27). Similarly, there was a statistically 
significant earlier mean age of MDD onset in those TRMD 
patients reporting a first or second degree relative with BP 
(mean = 18.3 years, SD = 6.7, N = 16) compared to those report-
ing no bipolar relatives (mean = 25.7 years, SD = 14.7, N = 62; 
t = 2.9, p = 0.005). This relationship supports the hypothesis that 
a subset of TRMD patients may represent a variant of BP. This is a 
potentially critical observation, as it may suggest the need for dif-
ferent clinical therapeutic approaches in these patients (29–33).
The TRMD clinic patients have spent almost half their lives 
in a depressed state: (mean of about 20 years depressed; range 
5–50  years). Recurrent episodes are the norm, although 30% 
report one continuous episode of MDD. Based on MADRS 
scores, 90% of patients exhibit moderate to severe symptoms at 
FiGURe 2 | The graph shows the age of onset of MDD in the 79 patients evaluated in the TRMD clinic. The bars show the mean age of onset of MDD in 
these subjects according to family history including family members with MDD and bipolar disorder (BP). This figure has been adapted and modified from data 
presented in Ref. (25).
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the time of first evaluation. As supported in the literature, treat-
ment resistance is a significant risk factor for suicide attempts: 
25% have attempted suicide at some point in their life with an 
average of 3.4 suicide attempts per individual with an attempt 
(34, 35). Almost two-thirds (63%) of these patients have been 
hospitalized for depression and 33% are on disability. Similar to 
non-TRMD MDD, women outnumbered men by 2–1, consistent 
with other TRMD studies (16, 17, 23, 26, 27).
Treatment-resistant major depression patients evaluated at 
the Washington University TRMD Clinic could be considered 
“hyper-resistant”: on average, these patients have failed 8 “ade-
quate” treatment trials at the time of index evaluation (Figure 3). 
The most common treatment trials were with SSRIs (99% of 
patients): on average patients have received 3.6 trials of an SSRI, 
either alone or in combination with other treatments. SNRIs had 
been tried in 95% of subjects, bupropion in 89%, and evidenced-
based forms of psychotherapy in 93%. Augmentation trials in 
which specific medications are added to ongoing treatment with 
a standard antidepressant were common with 86% receiving 
an antipsychotic (typically aripiprazole, or quetiapine), lithium 
(58%), stimulants (54%), thyroid supplementation (34%), and/or 
buspirone (23%). Interestingly, first-generation antidepressants 
were less commonly used with only 57% having received a TCA 
and 37% a MAOI. Surprisingly, the most aggressive and arguably 
most effective treatment for TRMD, ECT, was only attempted in 
60% of these highly refractory individuals.
KeTAMiNe, NMDARs, AND RAPiDLY 
ACTiNG ANTiDePReSSANTS
The severe features of TRMD outlined above make it manda-
tory to find new and more effective treatments. Dating to 
studies initiated in the 1990s, there is increasing evidence that 
the dissociative anesthetic, ketamine, has rapid antidepressant 
effects in subjects with MDD and TRMD. Importantly, the 
antidepressant effects of ketamine are observed with a single 
intravenous administration of a subanesthetic dose, with most 
studies using 0.5 mg/kg infused over 40 min. In the initial pilot 
report, Berman et al. (7) described seven subjects with MDD who 
showed significant improvement in depressive symptoms within 
72 h following ketamine administration. Zarate and colleagues 
(36) pursued this finding and reported significant benefits in 18 
subjects with TRMD. These individuals showed improvement 
in depression ratings 2 h following ketamine infusion. By 24 h 
after ketamine about 70% showed a response (50% reduction in 
depression scores), and about 30% were in remission (having few 
or no symptoms). Thirty-five percent of subjects maintained the 
benefits 1 week after ketamine. Ketamine was fairly well tolerated 
although there were transient increases in psychotic symptoms 
during drug infusion.
The dose of ketamine used in these studies and in most studies 
to date is the same as originally used by Krystal and colleagues 
(9) in the early 1990s. In the initial studies, 19 healthy volunteers 
received a 40 min infusion of ketamine at a dose of 0.5 mg/kg. 
The purpose of these studies was to determine whether ketamine 
mimicked the symptoms of schizophrenia as a model to study 
factors involved in psychosis. The subjects experienced tran-
sient changes in perception (sensory illusions), altered thought 
content (persecutory ideas), amotivation (a disconnected state), 
and cognitive impairment (diminished attention, problems with 
word fluency and diminished ability to learn new information). 
Thus, the same dose of ketamine now being used routinely in 
studies of TRMD is clearly associated with psychotomimetic 
and cognitive effects, prompting concerns about the safety and 
FiGURe 3 | The graph shows the number of antidepressant trials documented in 79 patients evaluated in the TRMD clinic. Based on chart review and 
clinical interview, all trials listed in this graph had adequate dose and duration of antidepressant treatment.
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tolerability of ketamine in individuals with psychiatric illnesses. 
Fortunately, in studies to date the psychotomimetic and cogni-
tive symptoms have been transient, although ketamine also has 
effects on heart rate and blood pressure that may limit its use 
in certain patient populations. Administration of ketamine in 
these studies and subsequent studies was not accompanied by 
agents, such as GABA-enhancing agents or antimuscarinics (37), 
to prevent psychotomimetic side effects. It is unknown whether 
the use of “safening” agents would alter the antidepressant effects 
of ketamine.
Since the original human studies of the 1990s, work on keta-
mine has progressed with emphasis on defining patient groups 
and symptoms particularly responsive to the drug. A recent meta-
analysis of seven clinical trials involving 147 patients supports the 
hypothesis that ketamine has rapid but transient antidepressant 
effects after a single administration, with odds ratios for antide-
pressant response and remission of 9.87 and 14.47, respectively, 
24 h following treatment and effects fading over 1–2 weeks (38). 
A recent Cochrane review, however, was more restrained and 
raised cautionary notes about small sample sizes and risk of bias 
(39). Efforts to prolong the antidepressant effects of ketamine 
have included repeated infusions, following approaches used for 
ECT (40). For example, Murrough and colleagues (41) studied 
24 subjects with TRMD treated with six intravenous ketamine 
infusions administered three times per week over 12 days. This 
group of TRMD patients showed a 71% acute response rate, with 
initial effects manifest within 4 h of infusion. The repeated expo-
sures had some beneficial effect, but the median time to relapse 
was 18 days even with six treatments. An alternative approach 
to prolong the effects comes from the analgesia literature where 
longer ketamine infusions are used to treat chronic regional pain 
syndrome (CRPS). Ketamine infusions to treat CRPS have ranged 
from several hours to several days. For example, Dahan et al. (42) 
infused ketamine at a dose of 5–20 mg/h for 100 h. This prolonged 
treatment led to a 67% response rate (vs. 21% for placebo) and 
effects lasted about 50 days. Whether such an approach would 
be tolerated or effective in TRMD is unknown, but even longer 
ketamine infusions have been used elsewhere in chronic pain 
(43). Other efforts to prolong ketamine’s effects include intranasal 
administration (44).
Beyond TRMD, some evidence suggests that ketamine is 
effective in patients with refractory bipolar depression (45) and 
chronic post-traumatic stress disorder (PTSD) (46). Other stud-
ies indicate that ketamine may have beneficial effects on specific 
subsets of depressive symptoms including suicidal ideation (47, 
48). An interesting twist is that family history may predict keta-
mine response. At least two studies indicate that having a positive 
family history of alcohol abuse/alcoholism predicts antidepres-
sant response to ketamine (45, 49). Furthermore, prior studies 
indicate that recovered alcoholics and persons with high familial 
risk for alcoholism have altered responses to ketamine compared 
to naïve controls, with dampened psychotomimetic and dissocia-
tive symptoms (50–52).
KeTAMiNe MeCHANiSMS
Why ketamine? The seminal studies of Krystal and colleagues 
(9) were designed to test the hypothesis that hypofunction of 
NMDARs is involved in the pathophysiology of schizophrenia 
and other psychotic disorders (37, 53). In parallel, Trullas and 
Skolnick (54) proposed that NMDAR antagonists might have 
antidepressant effects based on studies in animals. NMDARs are 
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a class of glutamate-gated cationic channels in which the bind-
ing of glutamate promotes the opening of transmembrane ion 
channels that allow the influx and efflux of positively charged 
ions including Na+, K+, and Ca2+ (55). NMDARs are multimeric 
proteins with four subunits. The major NMDARs in mammalian 
brain express one of eight GluN1 splice variants along with one or 
more GluN2 subunits, or sometimes a GluN3 (GluN3A, GluN3B) 
subunit. GluN2 subunits (GluN2A-D) bind agonists (glutamate) 
in their extracellular domains, while GluN1 subunits, obligatory 
for a functional channel, regulate ion channel function by bind-
ing the co-agonists glycine or d-serine. Together the binding of 
glutamate and a co-agonist is required for opening (gating) of 
NMDAR ion channels (55, 56). Adding to the complexity, multi-
ple other endogenous ions and modulators also bind NMDARs 
to regulate ion channel function. These include ionic modulators, 
Mg2+, Zn2+, and H+, as well as polyamines, neurosteroids, and 
oxysterols (55–57). Mg2+ plays a key role in determining the 
properties of NMDARs, producing a form of voltage-dependent 
open channel block at membrane potentials near the neuronal 
resting membrane potential. When the membrane depolarizes, 
Mg2+ exits the NMDAR channel and this allows other cations to 
flow in and out of the cell. In effect, NMDARs pass very small 
currents at resting membrane potential, but open effectively when 
neurons are excited (depolarized). This voltage-dependence con-
tributes strongly to the proposed role of NMDARs as “coincidence 
detectors” because their activation requires both presynaptic 
(glutamate release) and postsynaptic activation (depolarization) 
(55, 56). When both conditions occur, NMDARs participate in 
excitatory synaptic function. In turn, activated NMDAR chan-
nels are highly permeable to Ca2+, and the influx of Ca2+ activates 
second messenger systems and promotes Hebbian synaptic 
plasticity, including long-term potentiation (LTP) and long-term 
depression (LTD), forms of lasting synaptic change thought to 
underlie learning and memory (58).
In the 1980s, a series of studies dating to David Lodge and 
colleagues (59) found that ketamine, its structural analog, phen-
cyclidine (PCP), and the experimental agent, MK-801, are non-
competitive/uncompetitive NMDAR antagonists. These agents 
inhibit responses mediated by NMDARs, but do not alter the 
binding of agonists to NMDARs unlike competitive antagonists 
(60). Biophysical experiments showed that ketamine and its ana-
logs have unique mechanisms. These agents do not act on closed 
NMDARs. Rather, the ability of ketamine to block responses 
requires that NMDAR ion channels open (61, 62). When the ion 
channels are open, ketamine enters the channel and binds a site 
that is electrically deep within the channel pore to occlude the 
flow of ions. In contrast, memantine, another NMDAR channel 
blocker also binds a superficial site within the channel, perhaps 
accounting for differences from ketamine (63). When ketamine 
binds the deep site, the ion channel is able to close around the 
blocking molecule creating a longer-lived ion channel block. This 
is referred to as “trapping ion channel block” (61, 63). Relief of 
this block requires that glutamate (or other agonist) binds the 
receptor to promote channel opening. Depolarization of the 
neuronal membrane speeds blocker dissociation. As mentioned, 
ketamine shares these properties with PCP and MK-801, but is 
less potent than the other two agents, resulting mainly from faster 
dissociation from the open channel. While block of NMDARs is 
not the only effect of ketamine, and effects on other receptors and 
channels likely contribute to some pharmacological actions, the 
effects of ketamine on NMDARs appear to play critical roles in 
the ability of this agent to produce anesthetic, psychotomimetic, 
analgesic and possibly antidepressant effects. NMDARs are also 
likely to underlie the abuse potential of ketamine.
How ketamine produces its beneficial effects at cellular and 
molecular levels is an area of active investigation. Importantly, the 
effective antidepressant doses of ketamine are subanesthetic and 
at these concentrations, ketamine only partially inhibits NMDAR 
currents with responses mediated by AMPA-type glutamate 
receptors and unblocked NMDARs remaining intact (likely <50% 
NMDAR block in the presence of physiological Mg2+) (64–67). 
Studies in animals and in  vitro indicate that ketamine has dis-
inhibitory effects in neocortex that may result from preferential 
dampening of excitation of GABAergic interneurons resulting in 
stimulation of pyramidal (excitatory) neurons (68). Preferential 
inhibition of NMDARs in select cell types might be achieved 
through the complex dependence of ketamine block on agonist 
presentation, third-party endogenous modulators (e.g., positive 
allosteric modulators, Mg2+), and activity levels (64, 69, 70).
Because ketamine’s antidepressant effects greatly outlive 
psychotomimetic effects and systemic drug presence, it is likely 
that ketamine triggers persistent biochemical, synaptic and/
or morphological changes. Consistent with this idea, ketamine 
indirectly enhances AMPAR-mediated excitatory synaptic func-
tion in frontal cortex (71) and hippocampus (72), resulting in 
persistent increases in synaptic efficacy and changes in neuronal 
structure. Other key targets for ketamine’s antidepressant effects 
in rodents appear to include infralimbic prefrontal cortex (73). 
Mechanisms contributing to synaptic enhancement may dif-
fer between regions. In frontal cortex, synaptic enhancement 
involves activation of the mammalian target of rapamycin 
(mTOR) kinase and effectors downstream of mTOR (71, 74, 75), 
while in hippocampus effects on eukaryotic elongation factor 
2 kinase contribute (72). Other key components of ketamine-
induced signaling appear to include brain-derived neurotrophic 
factor (BDNF) and perhaps glycogen synthase kinase 3β (72, 
74). Effects of ketamine in rodent hippocampus may specifically 
involve effects on spontaneous synaptic transmission (72, 76).
Some evidence suggests that effects of ketamine on a specific 
subtype of NMDARs expressing GluN2B subunits may be par-
ticularly important in synaptic and behavioral effects in animals 
(77), and that activation of non-GluN2B expressing NMDARs 
that are not blocked by ketamine may drive some of the synaptic 
and metaplastic effects of ketamine on hippocampal network 
function (78). The latter findings are also consistent with data 
indicating that a selective inhibitor of GluN1/GluN2B NMDARs 
has antidepressant efficacy in humans (79). Other work indicates 
that selective blockade of NMDARs expressing either GluN2A or 
GluN2B has antidepressant-like effects whereas concurrent block 
of both subtypes results in stereotyped and possibly psychotic-like 
behaviors (80). It is interesting to note that these subunit selective 
blockers act through different pharmacological mechanisms than 
ketamine; they are not channel blockers. Data also indicate that 
activation of AMPARs, the primary mediators of fast glutamatergic 
December 2015 | Volume 6 | Article 1727
Zorumski et al. Nitrous Oxide and Depression
Frontiers in Psychiatry | www.frontiersin.org
transmission are important in the effects of ketamine (71, 72), but 
it is unclear whether this involves specific downstream effects of 
AMPARs or the fact that depolarization mediated by AMPARs is 
important for activation of unblocked NMDARs.
KeTAMiNe AND BRAiN CiRCUiTS
Several studies have begun to address how ketamine affects 
human brain circuitry involved in cognition, motivation, and 
emotion. Some evidence using functional magnetic resonance 
imaging (fMRI) suggests that depression reflects a state of 
functional resting state hyperconnectivity among several brain 
networks including the default mode network that processes 
internal (self) information and networks underlying cognitive 
control and affective processing. Increased connectivity in these 
networks appears to involve increased activity in regions of 
dorsal medial prefrontal cortex referred to as the “dorsal nexus” 
and improvement in depressive symptoms is associated with 
dampened dorsal nexus activity (81). Scheidegger and colleagues 
(82) found that within 24 h after infusion of ketamine in normal 
subjects, there was diminished resting state connectivity of the 
default mode, cognitive control, and affective networks with the 
dorsal nexus, suggesting a plausible brain circuitry mechanism 
for antidepressant actions. Other work indicates that ketamine 
acutely dampens both the activation and deactivation of brain 
regions involved in a working memory task, although these latter 
findings may be more relevant to changes associated with schizo-
phrenia and ketamine-induced psychotic symptoms (83, 84). 
Ketamine also produces acute glutamate-mediated hippocampal 
hypermetabolism, and this may contribute to interneuron dys-
function and acute psychotic symptoms (85).
Recent work using magnetoencephalography to map changes 
in regional brain interactions found that subanesthetic ketamine 
decreases the apparent gain of pyramidal neurons in parietal cor-
tex, with diminished glutamate-mediated connectivity between 
frontal and parietal regions (86). Changes in the signal-to-noise 
ratio of information processing in lateral prefrontal neurons have 
also been observed during working memory tasks in macaques 
following subanesthetic ketamine (87). Taken together with 
studies in rodents, it appears that ketamine may enhance excita-
tory synaptic function in some brain regions (e.g., hippocampus 
and frontal cortex) while dampening excitatory connectivity in 
regions that are overactive in MDD (e.g., default mode, affective 
and cognitive control networks, and dorsal nexus).
OTHeR NMDAR ANTAGONiSTS: NOT ALL 
ARe ANTiDePReSSANT
The clinical results with ketamine in TRMD have prompted a 
search for other NMDAR antagonists that share ketamine’s rapid 
antidepressant actions while having fewer side effects (88). These 
include agents with more selective actions at NMDAR subtypes, 
including selective GluN1/GluN2B NMDAR antagonists (79) as 
well as NMDAR antagonists that modulate glycine/d-serine sites 
on NMDARs, and others that have different effects on NMDAR 
channels (88–90). Although some candidate NMDAR antagonist 
antidepressants are not channel blockers, not all NMDAR chan-
nel blockers have significant antidepressant effects. For example, 
memantine, an agent used to slow progression in Alzheimer’s 
disease, is a non-competitive NMDAR antagonist and channel 
blocker with limited antidepressant efficacy (17, 91). The lack of 
antidepressant efficacy may result from pharmacokinetic differ-
ences and/or selective effects of memantine on NMDAR channels 
and subtypes (92, 93). On the other hand, differences between 
memantine and ketamine on NMDAR currents have been dif-
ficult to demonstrate in spontaneously active neuronal networks 
(70) unless third-party positive modulators of NMDARs are 
present (71). Thus, key pharmacological features predicting anti-
depressant effects are murky at the moment, and an empirical, 
trial-and-error approach appears warranted.
NiTROUS OXiDe AS A RAPiDLY ACTiNG 
ANTiDePReSSANT
Nitrous oxide is an inhalational anesthetic with analgesic and 
anxiolytic actions that has been in clinical use for more than 
150 years (94). Acute euphorogenic effects of nitrous oxide (hence 
the name “laughing gas”) have also led to recreational use and 
abuse, and speculation that it might have antidepressant proper-
ties (95). In the late 1990s, nitrous oxide was found to be a non-
competitive NMDAR inhibitor, acting by a mechanism distinct 
from ketamine and not involving open channel block (10, 96). 
Based on these early findings and evolving results from antide-
pressant studies of ketamine, Nagele and colleagues (11) pursued 
a pilot, proof of concept clinical trial using a subanesthetic dose of 
nitrous oxide in a group of 20 patients with TRMD. The dose used 
for this study was 50% nitrous oxide with 50% oxygen inhaled 
for 1  h in a single session. This dose was selected based on its 
routine use for analgesia and mild sedation in anesthesiology and 
dentistry. The effects of nitrous were compared to a placebo gas 
mixture (50% nitrogen − 50% oxygen × 1 h) in a double-blind, 
cross-over design with nitrous oxide and placebo administered 
1 week apart. Patients were required to have failed at least two 
adequate trials of antidepressant treatments in the current episode 
of MDD while having a baseline depression score on the HDRS 
above 18. The trial excluded patients with BP, psychosis, panic dis-
order, obsessive–compulsive disorder, personality disorders, and 
active substance use disorder within the past 12 months except for 
nicotine. Also excluded were individuals with acute medical ill-
nesses, acute suicidal behavior and prior treatment with ketamine 
or ongoing ECT. Patients were required to remain on their routine 
antidepressant treatments for 4 weeks prior to and during the trial.
Patients enrolled in this study averaged 48 years of age, were 
60% women, and had experienced a mean lifetime history of 
19  years of MDD and eight documented antidepressant fail-
ures; four had failed ECT and three had failed VNS; thus, the 
patients studied with nitrous oxide mirrored the patients in 
the TRMD Clinic and involved individuals with a high degree 
of treatment refractoriness (25). Interestingly, 10 patients had a 
history of migraine headaches and 4 had a history of corrected 
hypo thyroidism. Significant improvement in depression ratings 
in this highly treatment-resistant cohort were observed at 24 h 
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after nitrous oxide administration with a median reduction of 
5.5 points on HDRS (95% CI −2.5 to −8.5 points), the primary 
endpoint for the study. Four patients were rated as showing a 
response to treatment (50% decrease in HDRS) and one of these 
individuals showed remission of MDD symptoms (HDRS < 7) 
compared to one patient with response to placebo and no 
placebo-treated patients with remission. MDD symptoms that 
were particularly sensitive to nitrous oxide included depressed 
mood, suicidal ideation, guilt, and psychological symptoms of 
anxiety. A significant subset of those patients experiencing an 
antidepressant response to nitrous inhalation maintained their 
response at 1 week. This latter feature confounded the cross-over 
study design because benefits were still observed at the time of the 
subsequent treatment. Nitrous oxide was well tolerated and side 
effects were short-lived following termination of nitrous adminis-
tration. Side-effects included nausea and vomiting, headache and 
increased anxiety/panic, and necessitated shortening the dura-
tion of nitrous administration in 5 of the 20 patients (vs. none of 
the placebo administrations).
NiTROUS OXiDe AND NMDARs
How does nitrous oxide produce its effects? Studies in the 
late 1990s provided the first evidence that nitrous oxide is a 
non-competitive NMDAR antagonist. In these studies, nitrous 
blocked NMDAR-activated currents in cultured hippocampal 
neurons with an approximate half-maximal effective concentra-
tion (EC50) of 30–40% (95). Even at 80%, however, nitrous was 
only a partial inhibitor of NMDAR responses producing less than 
70% block. Unlike ketamine, nitrous oxides effects were weakly 
voltage-dependent and did not display the kinetic effects on 
NMDAR currents expected of an open channel blocker, includ-
ing having no effect on the decay of NMDAR-mediated synaptic 
currents (10). Nitrous oxide had minimal effects on GABA-A 
receptors, with very weak (~20%) potentiation observed at 
80% nitrous. Weak effects were also observed on AMPA/kain-
ate type glutamate receptors (non-NMDARs) with about 30% 
block of kainate currents (mediated mainly by AMPARs in this 
preparation) at 80% nitrous. Effects on AMPAR currents were 
not voltage dependent. Nitrous had small inhibitory effects on 
synaptic currents mediated by AMPARs but did not alter paired-
pulse plasticity of these responses. This latter effect is important 
because it indicates that nitrous oxide is unlikely to have large 
presynaptic effects on glutamate transmission. Consistent with 
this, nitrous oxide failed to inhibit high voltage activated (HVA) 
calcium currents; HVA currents provide the calcium signal that 
triggers synaptic glutamate release.
The effects of nitrous oxide as an NMDAR antagonist in 
hippocampal neurons were consistent with histological changes 
observed in the cortex of rodents in vivo. Prior studies showed that 
NMDAR antagonists, including ketamine, produce vacuoles in 
neurons in the posterior cingulate cortex following systemic admin-
istration (37). Nitrous oxide mimicked these effects (96). Similarly, 
NMDAR antagonists block glutamate-mediated excitotoxicity and 
nitrous oxide mimicked these effects as well. Thus, physiological 
and histological studies indicate that nitrous oxide has NMDAR 
antagonistic, neuroprotective, and neurotoxic actions.
NiTROUS OXiDe AND BRAiN CiRCUiTS
To date, few studies have examined how nitrous oxide alters 
neuronal network activity. In the CA1 region of rat hippocampal 
slices, acute nitrous perfusion resulted in disinhibition of popula-
tion spike firing without significant effects on AMPAR-mediated 
synaptic potentials (97). The disinhibition was occluded by pic-
rotoxin, a GABA-A receptor antagonist, suggesting that nitrous 
oxide altered local synaptic inhibition in the CA1 region. In these 
studies, the lack of effect of nitrous oxide on excitatory synaptic 
potentials in the CA1 Schaffer collateral pathways suggests that 
its actions may differ from ketamine (72). However, the nitrous 
oxide studies were done in hippocampal slices from juvenile 
rats and ketamine’s ability to enhance CA1 synaptic responses 
appears to be age-dependent and most prominent in slices from 
adult rodents (98). Nonetheless, the disinhibitory effects on CA1 
function observed in young rodents is consistent with apparent 
changes in population spike firing observed with ketamine at the 
same age (78) and studies of ketamine in cortex (68).
There is limited information about the effects of nitrous oxide 
on human brain networks. Studies using quantitative electro-
encephalographic (EEG) recordings indicate that nitrous oxide 
dampens functional connectivity in superficial parietal networks 
with more widespread changes in frontal activity (99). Other 
work has found that nitrous oxide (at 20–40%) acutely decreases 
frontal slow wave (delta) activity, but this is followed by enhanced 
theta activity after drug washout (100). These EEG effects of 
nitrous differ from other general anesthetics. Studies examining 
the effects of nitrous on connectivity of brain networks underly-
ing depression are lacking.
Few studies have directly linked nitrous oxide’s effects on 
NMDARs to specific behaviors. In the roundworm, Caenorhabditis 
elegans, Nagele and colleagues (101) found that nitrous oxide 
alters motor reversal behavior. These effects of nitrous were 
not observed in animals lacking functional NMDARs, but were 
present in worms with altered expression of non-NMDARs. 
Furthermore, nitrous oxide inhibited motor reversal behavior 
upon re-expression of NMDARs in the NMDAR mutant worms. 
At 70%, nitrous oxide had no effect on chemotaxis, feeding, 
defecation or rate of locomotion. Some evidence in mice with 
targeted deletion of the GluN1 NMDAR subunit indicates that 
NMDARs are involved in the sedating effects of nitrous oxide 
(102), although this finding has not been replicated in other 
studies and secondary effects on monoaminergic activity may 
be important for immobility in GluN1 knockout animals (103). 
Other work suggests that discriminative stimulus effects of 
nitrous oxide at least partially involve NMDARs (104).
eFFeCTS OF NiTROUS OXiDe ON 
vOLTAGe-ACTivATeD CALCiUM 
CHANNeLS
The analgesic effects of nitrous oxide have prompted studies 
examining whether the drug alters ion channels or signaling sys-
tems involved in pain processing other than NMDARs. Todorovic 
and colleagues (105) found that nitrous oxide is a weak inhibitor 
FiGURe 4 | The list includes various effects of nitrous oxide that could 
contribute to antidepressant and other CNS effects. Supporting studies 
are described in the text.
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of low voltage activated (LVA, T-type) calcium channels, produc-
ing about 30% depression of LVA currents at 80% nitrous in rat 
sensory neurons. Interestingly, the ability of nitrous to block LVA 
currents is selective for the Cav3.2 LVA subtype that is expressed 
in sensory neurons, with no effect on Cav3.1. Other studies using 
site directed mutagenesis have found that effects on Cav3.2 likely 
involve metal catalyzed oxidation (MCO) at histidine 191 (H191) 
(106, 107). MCO is a form of the redox modulation that is known 
to alter the function of multiple ion channels including LVA chan-
nels (108) and NMDARs (109). Consistent with this, Orestes et al. 
(106) showed that nitrous oxide generates reactive oxygen species 
(ROS) in the presence of iron, and metal chelators (that scavenge 
iron) and catalase (a ROS scavenger) attenuate effects of nitrous 
on LVA channels. Furthermore, mutant mice with targeted dele-
tion of Cav3.2 show diminished analgesia in response to nitrous 
oxide, indicating that this channel is relevant to peripheral anal-
gesic effects of nitrous oxide in vivo. Similarly, EUK-134, an agent 
that mimics superoxide dismutase and catalase, also dampens 
nitrous oxide-induced analgesia (106). Nitrous oxide does not 
inhibit high voltage activated (HVA) calcium currents in sensory 
or hippocampal neurons (10, 105).
OTHeR POTeNTiAL MeCHANiSMS OF 
NiTROUS OXiDe
Nitrous oxide has other effects that could contribute to its clinical 
and behavioral actions, particularly analgesia (Figure 4). These 
include the ability to activate the two pore-domain potassium 
channel, TREK-1 (110), as well as to weakly block GABA-C 
receptors and serotonin-type 3 receptors (111). Nitrous is also 
a partial inhibitor of certain nicotinic acetylcholine receptors, 
producing 40% inhibition of α4β2 nicotinic receptors but only 
7% inhibition of α4β4 receptors (111). Other evidence indicates 
that nitrous oxide has opioid-like effects that could contribute 
to analgesia and perhaps to psychotropic effects (112–115). 
Nitrous oxide also has effects on brainstem adrenergic neurons 
and activation of α-adrenoceptors in brainstem and spinal cord 
contribute to antinociceptive effects in rats (116, 117).
It is difficult to compare the potency of nitrous oxide for effects 
on various targets across studies because complete concentration-
response data are not available for many effects. Nonetheless, 
nitrous oxide blocks NMDARs by 50% at a concentration of 
30%, making this one of its most potent effects (96). Effects on 
opiate receptors are also potent with 30% nitrous having analge-
sic actions equivalent to 10–15 mg morphine (118). Actions at 
T-channels (30% block at 80% nitrous) (105) and TREK-1 (30% 
activation at 80% nitrous) (110) are weaker.
In addition to analgesia and anesthesia, nitrous oxide is used 
clinically for anxiolytic effects. Consistent with this, acute nitrous 
oxide shows anxiolytic properties in the elevated plus maze (119), 
light-dark exploration (120), social interaction (121), and condi-
tion burying tests (122) that are used as animal models of anxiety. 
These effects have been observed during 15–30 min exposures to 
nitrous oxide at concentrations of 25–75%. How nitrous oxide 
produces these effects is not certain, although some evidence sug-
gests a role for serotonin and GABA-A/benzodiazepine receptors 
(123) and the release of the endogenous messenger, nitric oxide 
(NO) (118, 124). Cyclic GMP, a messenger activated by NO, also 
appears to participate in the anti-anxiety effects of nitrous oxide 
in rodents (125). NO has presynaptic effects on glutamate release, 
and nitrous oxide dampens NMDAR-mediated synaptic responses 
in the amygdala by both postsynaptic and presynaptic actions 
(126). Zarate and Machado-Vieira (127) postulated that the ability 
of nitrous oxide to generate NO may be important in its antide-
pressant actions. Consistent with this, some synaptic and memory 
impairing effects of ketamine involve NO synthesis (78, 128).
ONGOiNG iSSUeS AND FUTURe 
CONSiDeRATiONS
Studies examining the acute antidepressant effects of ketamine 
and other NMDAR antagonists are a growth area in psychiatry, 
providing inroads into what may be truly novel targets and treat-
ments for MDD and TRMD (8, 88). The ability of these agents to 
rapidly dampen suicidal ideation leads to the intriguing possibility 
of administering ketamine-like drugs in emergency and inpatient 
settings while other antidepressant strategies are initiated. Despite 
encouraging results there are major challenges with the use of 
ketamine, including acute psychotomimetic and cognitive-
impairing actions, along with abuse potential. It is also important 
to remain cognizant of the challenges that have plagued attempts 
to develop NMDAR antagonists as treatments for neurodegen-
erative conditions, including neurotoxic effects (37).
The recent pilot findings with nitrous oxide for TRMD are 
intriguing and indicate that mechanisms other than channel 
block for inhibiting NMDAR function may be effective for treat-
ing patients with severe and refractory mood disorders. Like 
ketamine, nitrous oxide appears to have rapid beneficial effects 
on suicidal ideation. Importantly, while nitrous oxide, like keta-
mine has abuse potential, it does not appear to share ketamine’s 
psychotomimetic or cognitive side effects, making it an attractive 
alternative for therapeutic development. Nitrous oxide is known, 
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however, to impair methionine synthesis via inactivating effects 
on vitamin B12 (cobalamin), particularly following repeated or 
prolonged administrations (94). In the pilot antidepressant trial, 
a single 1 h administration of nitrous oxide did not alter vitamin 
B12 activity (11).
As is true of any pilot study, there are now many more 
questions than answers including questions that are relevant 
for ketamine (129). The pilot nitrous oxide study used a single 
dose and a single 1-h administration. The dose (50% nitrous 
oxide) was based on use in anesthesiology and dentistry, while 
the duration (1 h) was selected to mimic ketamine infusions 
for TRMD. Despite initial positive results, it is unclear whether 
either of these parameters is optimal or whether lower doses 
and altered durations of exposure would maintain or improve 
benefits while diminishing acute side effects and enhancing 
patient tolerability during nitrous inhalation (100). Similar to 
ketamine, it is unclear how long the benefits of nitrous oxide 
last and how to sustain the benefits. The pilot study was con-
ducted in highly refractory TRMD subjects; whether nitrous 
oxide will have a different impact in less refractory patients 
requires further study. Similarly, we have no information 
about the response of MDD in the context of other psychiatric 
disorders including BP, anxiety disorders, personality disorders 
and substance use disorders, or whether nitrous oxide will 
be effective in acute inpatient settings. While nitrous oxide 
is relatively easy to use in outpatient settings such as dental 
offices, monitoring cardiovascular and respiratory parameters 
as well as recovery from sedation will be important for use in 
psychiatry. Potential neurotoxic effects of nitrous oxide (and 
ketamine) also must be considered with high doses and more 
prolonged administration (96).
Another major issue in studies of rapid antidepressants 
concerns how best to measure changes in depression. Current 
instruments (e.g., HDRS, MADRS, and BDI) are limited and 
query symptoms that are of longer duration and less amenable 
to acute change (e.g., sleep disturbances, appetite, and weight 
changes). Thus, the validity of these instruments when dealing 
with rapid changes requires further evaluation. Efforts using 
other instruments, perhaps including visual analog scales and/
or ecological momentary assessments may be more appropriate 
going forward.
Similar to other drugs, including ketamine, nitrous oxide is 
not specific for NMDARs and alters the function of a number 
of other ion channels and proteins involved in neural signaling. 
Nonetheless, effects on NMDARs are among the most potent 
effects of this agent, making it likely that NMDAR inhibition 
contributes, at least in part, to clinical effects, just as it likely 
does for ketamine. Although the NMDAR effects of ketamine 
may be modulated by regional or temporal differences in agonist 
presentation, depolarization state of cells, and by presence of local 
endogenous allosteric regulators (63, 69), the effects of nitrous 
oxide do not involve ion channel block, particularly the longer-
lived trapping block associated with ketamine-type agents (10). 
Thus, effects of nitrous oxide may be less prone to environmental 
conditions. Also, the acute effects of nitrous oxide are faster to 
reverse once administration is stopped.
Whether nitrous oxide’s effects on NMDARs involve redox 
modulation as they do at LVA (T-type) calcium channels (106) 
remains to be determined. If this is the case, it opens up the 
possibility of developing other agents that target this mecha-
nism, although specificity of effects could be a major problem. 
Unlike ketamine, however, nitrous oxide is not metabolized 
endogenously to other moieties that are bioactive (67, 130, 131), 
and both ketamine and its metabolites affect targets other than 
NMDARs that contribute to sedation and CNS effects (132). 
Furthermore, in the United States ketamine is sold as a mixture 
of S- and R-enantiomers; the S-enantiomer (which is what is used 
in Europe) is more potent but the R-enantiomer has biological 
activity (133). Thus, despite enthusiasm over the early work on 
ketamine and pilot results from nitrous oxide, it is premature to 
conclude that effects on NMDARs are the sole mechanism for 
antidepressant actions (129).
The clinical trial with nitrous oxide was based on the 
evolving literature on ketamine. There are other NMDAR 
antagonists used clinically that could also be potentially 
developed for therapeutic purposes in psychiatry. Examples 
include the gaseous anesthetic, xenon (111, 134), the common 
intoxicant, ethanol (alcohol) (135), and the cough suppressant, 
dextromethorphan. Whether any of these agents would have 
antidepressant efficacy, particularly following acute systemic 
administration, is uncertain. Based on the lack of apparent 
antidepressant efficacy of memantine (91), however, it seems 
unlikely that all NMDAR antagonists will be useful as anti-
depressants. Nonetheless, understanding why memantine or 
these other agents do or do not have significant antidepressant 
effects may help clarify key mechanisms underlying psycho-
tropic actions. In fact, preclinical studies with memantine 
have already pointed to differences in the ability of this agent 
to modulate spontaneous synaptic activity and to enhance syn-
aptic efficacy in the rodent hippocampus relative to ketamine 
(93). Differences in pharmacokinetics and route of administra-
tion may also be key variables. Other considerations, include 
the fact that effective doses of ketamine and nitrous oxide are 
subanesthetic (65), indicating that at the effective doses, these 
agents only partially inhibit NMDAR currents, resulting in a 
significant population of NMDARs that remain unblocked. 
Studies in rodents indicate that anesthetic doses of ketamine 
that block a higher percentage of NMDARS also block both 
antidepressant actions in rodents and synaptic effects in neo-
cortex (71). In hippocampus, complete block of NMDARs 
during ketamine administration (or high concentrations 
of ketamine alone) prevents synaptic and metaplastic 
effects of the drug in the hippocampus (78, 136). Whether 
similar effects occur with nitrous oxide and other NMDAR 
antagonists is unknown.
SUMMARY
Evolving work on NMDAR antagonists supports their 
importance as novel targets for therapeutic development 
in neuropsychiatry. Ongoing studies of ketamine and early 
results with nitrous oxide are encouraging. While neither of 
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these agents is a selective NMDAR antagonist, it is clear that 
NMDAR inhibition plays a role in their behavioral effects. 
Thus, nitrous oxide is another chapter in the NMDAR depres-
sion story and has the potential to open new avenues for rapid 
therapeutic effects against severe and refractory forms of 
MDD.
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